| scholarly article | Q13442814 |
| P50 | author | Sylvie Urbé | Q57063712 |
| Judy M Coulson | Q61858338 | ||
| Liam P Cheeseman | Q63384838 | ||
| Hui Yi Chew | Q88092843 | ||
| P2093 | author name string | Michael J Clague | |
| Joseph J Sacco | |||
| Rachel Carter | |||
| Sarah Darling | |||
| Michael Denny | |||
| Jenna Kenyani | |||
| Zohra Butt | |||
| P2860 | cites work | Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O | Q24293775 |
| Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB | Q24309403 | ||
| Defining the human deubiquitinating enzyme interaction landscape | Q24315885 | ||
| BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression | Q24321439 | ||
| The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. | Q24323060 | ||
| Chfr is linked to tumour metastasis through the downregulation of HDAC1 | Q24324032 | ||
| Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1 | Q24329078 | ||
| Germline mutations in BAP1 predispose to melanocytic tumors | Q24594891 | ||
| Frequent mutation of BAP1 in metastasizing uveal melanomas | Q24601069 | ||
| Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma | Q24606279 | ||
| COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 | ||
| Germline BAP1 mutations predispose to malignant mesothelioma | Q24635326 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation | Q24793292 | ||
| Prognostic significance of BRCA1-associated protein 1 in colorectal cancer | Q38397568 | ||
| Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis | Q38677842 | ||
| The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells | Q39051595 | ||
| Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma | Q39399033 | ||
| Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. | Q39455093 | ||
| SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer | Q39899561 | ||
| Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. | Q42757408 | ||
| Germline BAP1 mutations and tumor susceptibility | Q42760067 | ||
| BAP1 protein is a progression factor in malignant pleural mesothelioma | Q47734004 | ||
| Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma | Q57177515 | ||
| Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition | Q60643322 | ||
| BAP1 is a good prognostic factor in advanced non-small cell lung cancer | Q84729943 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Global quantification of mammalian gene expression control | Q28238103 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma | Q30457154 | ||
| Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma | Q33821055 | ||
| The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma | Q34190027 | ||
| Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma | Q34194566 | ||
| Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers | Q34218657 | ||
| Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing | Q34283714 | ||
| BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma | Q34373982 | ||
| The pathogenesis of mesothelioma | Q34522971 | ||
| Histone deacetylase inhibitors in cancer therapy | Q34659283 | ||
| Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. | Q35129478 | ||
| Novel therapies in phase II and III trials for malignant pleural mesothelioma. | Q35129535 | ||
| The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 | Q35160462 | ||
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 | ||
| Role for histone deacetylase 1 in human tumor cell proliferation | Q35948150 | ||
| BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs | Q36384018 | ||
| Discovery and development of SAHA as an anticancer agent | Q36745383 | ||
| Germline BAP1 mutations predispose to renal cell carcinomas | Q36909238 | ||
| The deubiquitylase USP15 stabilizes newly synthesized REST and rescues its expression at mitotic exit | Q37075932 | ||
| Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke | Q37139659 | ||
| Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies | Q37226511 | ||
| BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma | Q37355644 | ||
| Future developments in the management of malignant pleural mesothelioma | Q37449036 | ||
| Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair | Q37474898 | ||
| Loss of the tumor suppressor BAP1 causes myeloid transformation | Q37545704 | ||
| Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. | Q37825437 | ||
| Tumours associated with BAP1 mutations. | Q38070634 | ||
| Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer | Q38155850 | ||
| Transcription and beyond: the role of mammalian class I lysine deacetylases | Q38156341 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 13757-13771 | |
| P577 | publication date | 2015-05-30 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors | |
| P478 | volume | 6 |
| Q90642244 | Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine Melanoma |
| Q90294125 | BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers |
| Q33890512 | BAP1, a tumor suppressor gene driving malignant mesothelioma |
| Q27612411 | CIViC database |
| Q90699123 | Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer |
| Q27908468 | Consensus report of the 2015 Weinman International Conference on Mesothelioma |
| Q37619913 | Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. |
| Q101462858 | HDAC2-mediated proliferation of trophoblast cells requires the miR-183/FOXA1/IL-8 signaling pathway |
| Q28395597 | Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies |
| Q33710012 | Loss of nuclear BAP1 expression is associated with poor prognosis in oral mucosal melanoma |
| Q42728294 | Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? |
| Q39366003 | Malignant Mesothelioma: Time to Translate? |
| Q42700777 | Modulating BAP1 expression affects ROS homeostasis, cell motility and mitochondrial function. |
| Q57112789 | Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma |
| Q26750845 | Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs |
Search more.